We have shown that primary therapy with non-myeloablative (140 mg/m 2 ) high-dose melphalan (HDM) without hematopoietic support results in high response rates in untreated myeloma and very long-term survival of some patients. This study was designed to see if sufficient CD34
'operational cure' which signifies prolonged disease control with intensive therapy -continuous first complete remission (CR) for 10 years or longer. 1 The sequential therapeutic strategy we employ in myeloma -continuousinfusion induction chemotherapy, 2 high-dose melphalan (HDM) and autotransplantation 3 followed by maintenance therapy with interferon-␣2b 4 -results in complete remission (CR) rates approaching 60-70% 3 and median survival rates that are identical to those reported with tandem autotransplantation. 5 Despite these excellent response rates, it is unclear why the proportion of patients operationally cured is under 5%. The most significant characteristic distinguishing this minority of operationally cured patients from the rest is the speed with which they attained CR; 70% were in CR after induction chemotherapy compared with 9% of the other patients (P Ͻ 0.0001). 6 We have shown that patients responding faster to induction chemotherapy have a better outcome and the speed of response in patients given non-myeloablative HDM (140 mg/m 2 ; HDM140) as primary therapy is significantly faster than those receiving induction chemotherapy followed by myeloablative HDM (200 mg/m 2 ; HDM200). [7] [8] [9] This suggests the intriguing possibility that accelerating the speed of response in myeloma may result in improved outcome.
The modification of primary therapy with HDM140 without hematopoietic stem cell support to a sequence comprising infusional induction chemotherapy followed by HDM200 with autotransplantation resulted in even higher response rates. 3, 10, 11 Could a reversal of sequence -primary therapy with HDM200 followed by 'induction' chemotherapy -be even better? This would not necessarily happen through increased CR rates over the usual sequence (infusional chemotherapy followed by HDM200), but through increased speed of response and a higher proportion of patients attaining CR faster.
The use of HDM200 as primary therapy would require hematopoietic stem cell support using stem cells collected at presentation without prior cytoreduction; something which has not been attempted in myeloma to the best of our knowledge. This report outlines our first step towards using HDM200 as primary therapy with a view to increasing the proportion of 'operationally cured' patients -that of collecting stem cells at the time of presentation without prior cytoreduction. Preliminary data from the successor study of using upfront HDM200 is briefly described in this paper.
Patients and methods
Between October 1999 and January 2001, 31 newly diagnosed patients presenting to the Myeloma Unit of the Royal Marsden Hospital were enrolled on the study after providing written, informed consent. The study was approved by the local institutional review board (Trial Number 1720). Patients were staged using the Durie-Salmon system. 12 Patient characteristics are shown in Table 1 .
Stem cell mobilization
Patients received supportive therapy as needed in terms of hydration, analgesia, nutrition, transfusions and allopurinol. The stem cell mobilization regimen consisted of intravenous or oral methylprednisolone at the daily dose of 1 g/m 2 from day 1 to day 6, and subcutaneous granulocyte colony-stimulating factor (G-CSF; Filgrastim) at the daily dose of 12-16 g/kg from day 3 to day 6. The G-CSF dose was rounded off to the nearest 300 or 480 g pre-filled syringe size.
Leukapheresis
Leukapheresis was performed on 2 consecutive days (days 6 and 7; 4th and 5th day from start of G-CSF) using a Cobe Spectra cell separator (Gambro BCT; Cobe, Lakewood, CO, USA) running software version 4.7 (the mononuclear cell protocol). The greater of 10 l or 200% of the calculated blood volume was processed at each session lasting 2-2.5 h. 
Stem cell assessment and cryopreservation
Each leukapheresis product was subjected to the following investigations: total nucleated cell count, CD34 + cell estimation, mononuclear cell count, and CD38 + /CD138 + coexpression. Cells were cryopreserved with 10% dimethylsulfoxide using a controlled rate freezer, and were stored in the vapor phase of liquid nitrogen at Ϫ179ºC.
Therapy
The patients were to start induction chemotherapy as soon as possible after completion of stem cell collection. This comprised vincristine 0.4 mg/day and doxorubicin 9 mg/m 2 /day as a continuous i.v. infusion over 4 days, methylprednisolone 1.5 g i.v. or p.o. for 5 days and then tapered, and weekly cyclophosphamide 500 mg i.v. on days 1, 8 and 15 (C-VAMP). Cycles were repeated every 21 days until maximum response was achieved following which a final course was administered.
The plan was to harvest all the patients again after completing C-VAMP using single-agent G-CSF at the same schedule as before (without methylprednisolone), and then compare pre-and post-therapy collections.
Study endpoints
The primary aim of the study was to assess the proportion of patients in whom у1 ϫ 10 6 CD34 cells/kg could be harvested at presentation. The secondary aims were to assess the proportion of patients in whom у2 ϫ 10 6 CD34
+ cells/kg could be harvested, measure plasma cell contamination of the harvested material, assess toxicity associated with the harvest, and compare the post-C-VAMP stem cell collection to that at presentation. The response to therapy at the end of apheresis as well as after C-VAMP was assessed using the criteria described by Blade et al 13 which briefly are as follows: CR, disappearance of paraprotein in serum and urine by immunofixation for a minimum of 6 weeks, less than 5% plasma cells in marrow, no increase in size and number of bone lesions, disappearance of soft tissue plasmacytoma; partial remission (PR), Ͼ50% reduction in paraprotein for a minimum of 6 weeks, Ͼ50% reduction in marrow plasmacytosis and no increase in size and number of bone lesions; minimal response (MR), 25-49% reduction in paraprotein and marrow plasmacytosis; no response (NR), not fulfilling the criteria for MR or progressive disease.
Statistical analysis
Historical controls were selected from the prospectively maintained database of the Myeloma Unit. 14 These were 82 newly diagnosed myeloma patients harvested between August 1995 and September 1999. The selection was done by the in-house computer and was based on the following criteria: newly diagnosed myeloma patients who received infusional C-VAMP prior to mobilization, the dose of G-CSF was 12-16 g/kg for stem cell collection (patients during the same period who entered the Lenograstim-Filgrastim randomized trial and received a lower dose of G-CSF were excluded), CD34 values for the harvest were available. These were not consecutive patients. Some patients were not harvested if they proceeded to an allograft or died after C-VAMP or did not receive C-VAMP. The mobilization regimen comprised single-agent G-CSF at the dose of 12-16 g/kg daily as described for the study patients. Apheresis and cryopreservation protocols were identical to the study patients.
Continuous variables were compared using the KruskallWallis test or the Mann-Whitney test, and categorical variables using the 2 test. Correlation between continuous variables was determined using linear regression.
Results
One of the 31 patients enrolled on the study developed renal failure after 2 days of methylprednisolone and required hemodialysis. She received no methylprednisolone while on dialysis, and was taken off the study. She started C-VAMP after a week of hemodialysis. Renal function normalized in 2 months, and CR was attained after four cycles of C-VAMP. All analyses have been confined to the 30 patients who underwent apheresis at presentation. Table 1 shows the comparison of the study patients and historical controls. All study patients had, by definition, progressive disease and therefore had a significantly higher marrow plasmacytosis, serum paraprotein and calcium. The control patients had a lower Hb which was most likely due to prior C-VAMP chemotherapy. Of the 82 historical controls harvested after C-VAMP, 18 had achieved CR, 45 partial response (PR), and 19 were non-responders (NR). apheresis procedures. This proportion was lower than in the control group where 89% of the patients met the target with two apheresis procedures (P = 0.08). Twenty percent of the patients met the secondary target of 2 ϫ 10 6 CD34
Cell yields
+ cells/kg. This proportion was significantly lower than in the control group where 64% of the patients met the target with two apheresis procedures (P Ͻ 0.0001). The cell yields were also significantly lower in the study group.
Cell yields at the second harvest
Twenty-one (70%) patients were harvested again at the completion of between four and six cycles (median 4) of C-VAMP chemotherapy. Nine patients were not reharvested after C-VAMP: four received allogeneic transplantation as they were less than 55 years old and had donors; two died (one after the first course of C-VAMP with aspergillosis and one 3 weeks into treatment with cardiac arrest at home). Of the remaining three, one entered the upfront (immediate autograft, HDM200) study, one refused reharvesting and one awaits a second harvest. Table 3 shows the comparison of the pre-and post-therapy stem cell collections for these 21 patients. The CD34 + cell yield was significantly higher after therapy than before, as were the proportions of patients yielding у1 and у2 ϫ 10 6 CD34 + cells/kg. In all except three patients, the postchemotherapy collection was higher than that at presentation. The nine patients who were not reharvested were comparable to the 21 who were ( Table 3) .
Six of the eight patients who did not meet the primary end point were harvested again following C-VAMP chemotherapy, and four of six did collect у1 x 10 6 CD34 + cells/kg. The 22 patients who met the primary endpoint were younger, had lower calcium levels and marrow plasmacytosis, and higher albumin, suggesting, perhaps, a lower tumor burden overall.
Correlation of presentation variables with stem cell yields
Higher marrow plasmacytosis correlated weakly with lower CD34 + cell yields (r 2 = 0.145, P = 0.04). Age, gender, paraprotein at diagnosis, absolute neutrophil count, white cell count and platelets at diagnosis had no influence on the CD34 + cell yield. The values at presentation have been divided into two groups: those of patients undergoing a subsequent harvest after chemotherapy (n = 21) and those of patients who were not harvested again (n = 9). P values represent comparisons between nine and 21 patients at presentation, and between presentation and post-chemotherapy values in the 21 patients undergoing repeat apheresis.
Plasma cell content of harvests
The median number of CD38 + /CD138 + cells harvested in the study patients on both apheresis days combined was 0.38 ϫ 10 6 cells/kg (range, 0-64.7; data available for 27 patients). This was significantly reduced after C-VAMP in 10 of the 27 patients tested (median 0.2 ϫ 10 6 /kg; range, 0.03-0.26; P = 0.007). Eight of these 10 showed a decline compared with the value prior to C-VAMP. The median pre-and post-therapy numbers in these 10 patients were 1.35 (range, 0.12-64.7) and 0.2 (range, 0.03-0.3), respectively (P = 0.003). The median percent change in the plasma cell content was Ϫ90 (range, Ϫ99 to +150). No studies were performed to determine the clonality of these cells.
Tolerance of the mobilization regimen and response
None of the patients complained of worsening of bone pain. The administration of methylprednisolone and G-CSF, as well as both leukapheresis procedures were tolerated well and no major side-effects were observed.
Of the 25 patients with IgG or IgA disease, 16 had the serum paraprotein levels reassessed at the end of stem cell collection. Thirteen of these 16 (81%) patients experienced a decline in the paraprotein level to some extent at the end of mobilization as result of methylprednisolone therapy. The median change in the paraprotein level was Ϫ36% (range, Ϫ65% to +40%). The paraprotein level increased in three patients 7%, 39% and 40%. Interestingly, none of these three attained CR after C-VAMP chemotherapy.
C-VAMP induction therapy and response
One of 30 patients eligible for C-VAMP therapy refused all further therapy after apheresis, developed renal failure due to progressive disease (and long-standing diabetes mellitus), and is undergoing dialysis currently without any specific therapy for myeloma. Another patient went on to receive HDM200 as primary therapy using the harvested cells (vide infra).
Twenty eight patients received a median of four courses (range, 1-6) of C-VAMP. Seven (25%) attained CR, 16 (57%) PR, and two (7%) NR. Two patients died (aspergillosis and cardiac arrest), and one was not evaluable (non-secretory disease; allografted after two courses of C-VAMP because of aggressive bone disease).
HDM200 as primary therapy
At the end of this study, we received approval from the institutional review board to use the stem cells collected during the study for HDM200 and autotransplantation as primary therapy of the disease (Trial Number 1812). After IRB approval of the successor study, the first eligible patient to satisfy the inclusion criteria of Ͻ65 years, good performance status, normal glomerular function rate, normal MUGA scan and CD34 у1 ϫ 10 6 cells/kg was autografted using these cells. The plan on the successor study was to administer, after HDM200 and autograft, four courses of C-VAMP for patients in CR or multiple courses of C-VAMP until maximum response in those not in CR, followed by interferon-␣2b maintenance.
The clinical course of the first patient is described. A 37-year-old man presented with stage IIIA IgA lambda disease and lambda light chain excretion in the urine. Blood counts, renal function and liver function were normal. The bone marrow was hypercellular with 60% atypical plasma cells. Serum M protein was 56 g/l, the 24-h urine total protein 0.24 g, serum IgG 1.8 g/l, IgA 67.9 g/l, IgM 0.2 g/l, and ␤2-microglobulin 7 mg/dl. The patient's cells were harvested according to the study protocol and a total of 1.05 ϫ 10 6
CD34
+ cells/kg were obtained. The patient received HDM200 followed by the cryopreserved stem cells. The post-autograft period was uneventful with 17 days to neutrophil recovery (0.5 ϫ 10 9 /l) and 16 days to platelet recovery (50 ϫ 10 9 /l). CR was demonstrated on day 35. Posttransplant consolidation with C-VAMP was started on day 42. Four courses were administered with no unusual sideeffects and adequate hematologic recovery to baseline posttransplant levels after each course. Cyclophosphamide was omitted from the third and fourth courses as the patient had a chest infection at the beginning of the third course, and the leukocyte count was low at the start of the fourth course (2 x 10 9 /l; absolute neutrophil count 0.8 ϫ 10 9 /l). The patient continues to be in CR and is now on interferon␣2b maintenance.
After this study was completed, we have been routinely collecting stem cells at presentation. Two more patients (both underwent a similar collection protocol as the original study and had two leukophereses) have been autografted using these cells. The CD34 + cell yield in one was 5. 
Discussion
This study shows that it is possible to collect у1 ϫ 10 6
CD34
+ cells/kg in three-quarters of newly diagnosed myeloma patients at presentation prior to starting any systematic cytoreductive therapy with two moderate-volume leukapheresis procedures. It was disappointing to see that only 20% of study patients achieved the aphereses yield of 2 ϫ 10 6
+ cells/kg which could have major implications in a larger study and may adversely affect the outcome of patients undergoing an autotransplant. It is possible that an increase in the number of apheresis procedures (to [3] [4] [5] , as well as the use of large-volume leukapheresis may increase this proportion to 100%, as well as increasing the proportion of patients in whom у2 ϫ 10 6 CD34 + cells/kg can be collected to substantially higher than 20%.
While hematologic recovery in the three patients autografted using these cells was prompt, but slower than usual possibly due to lower infused CD34 + cells, dose-modification of post-transplant C-VAMP was needed in two. This suggests that obtaining and transplanting a larger number of CD34 + cells is desirable. We have shown recently that infusion of a higher number of CD34 + cells is associated with superior event-free survival. 15 Additionally, a higher yield would also permit enough stem cells to be kept in reserve for a second autograft in the future, if needed. 16 Collection of stem cells at diagnosis in newly diagnosed myeloma patients has not been previously reported. This is at least in part due to the concern that collections prior to cytoreduction may be contaminated with significant numbers of malignant plasma cells which could contribute to post-transplant relapse. However, malignant cells are detected using sensitive techniques in the peripheral blood of all myeloma patients (including those in CR), and are present in virtually all blood stem cell harvests. [17] [18] [19] Boccadoro et al 20 showed that there was no correlation between the number of reinfused plasma cells and patient outcome. CD34 + selection has not been shown to confer any benefit
Bone Marrow Transplantation in myeloma. 21 These imply that the presence of a small number of plasma cells in the collected material may not be a major cause for concern. However, we did incorporate methylprednisolone in the mobilization regimen to act as in vivo purging. The combination of high-dose corticosteroids and G-CSF used for mobilization in this study was tolerated very well, and served as an excellent starting treatment for the disease, but it is quite possible that the use of methylprednisolone was also responsible for the inferior cell yields though it is more likely to be active disease (vide infra).
The fact that stem cell collections were inferior in the study patients compared with controls is almost certainly attributable to active disease. Disease activity may have some inhibitory or modulatory effects on cell surface adhesion molecules preventing the peripheralization of marrow stem cells. Indeed, response to therapy was associated with improvement in collections in almost all patients as the tumor load is less following C-VAMP and this may alter the marrow microenvironment and ability to mobilize the stem cells.
What about the patient who developed renal failure and was taken off study at the very start? It is quite likely that if the methylprednisolone had not been discontinued, we could have proceeded with the original study plan and apheresis. We feel that almost all, if not all, patients enrolled in a protocol such as this should be able to complete apheresis uneventfully.
Most patients had reduction in paraprotein with methylprednisolone used for mobilization. However, three of 16 (19%) patients had a rise in paraprotein during the collection procedure prior to C-VAMP. None of these three attained CR with C-VAMP. While it is difficult to draw any meaningful conclusions about the kinetics of response due to small patient numbers, it would be interesting to know if, as in acute lymphoblastic leukemia, 22 paraprotein response to corticosteroids early in the course of disease might serve as a predictor of response to subsequent therapy.
Based on these data, we are now undertaking a pilot study of administering HDM200 as initial therapy followed by C-VAMP (as post-autograft consolidation) to newly diagnosed patients with myeloma if the CD34 + collection is у1 ϫ 10 6 cells/kg. As described above, the three patients treated this way achieved CR with HDM200 and have tolerated post-transplant C-VAMP chemotherapy well. The value of upfront vs post-induction stem cell collection can only be assessed in a randomized trial. The inferior yields in this study may mitigate against such a strategy.
The 'operationally cured' patients described earlier 1 had attained CR significantly more quickly than others. The aim of primary therapy with HDM200 is to see if the proportion of 'operationally cured' patients can be increased by a strategy that could get patients into CR faster. With this approach, we also radically change our evaluation of efficacy of therapy in myeloma: instead of simply looking for an improvement in the median event-free survival with a procedure thought to be non-curative, we are seeking to increase the small proportion of patients who become very long-term survivors.
